PRQR

Kamada (KMDA) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -40.02%. A quarter ago, it was expected that this biopharmaceutical would post earnings of $0.09 per share when it actually produced earnings of $0.06, delivering a surprise of -33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Kamada, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $45.24 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.63%. This compares to year-ago revenues of $44.02 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kamada shares have added about 19.4% since the beginning of the year versus the S&P 500's gain of 8.1%. While Kamada has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kamada was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks h...

AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the quarter ended March 31, 2026, and provided a business update. “We are on track to deliver multiple clinical readouts within our current runway, including target engagement data for AX-0810 in the second quarter,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “We have refined our initial development strategy for AX-0810 to prioritize biliary atresia, where we believe we can generate the most meaningful clinical data in this target patient population, while maintaining flexibility to explore additional indications, including PSC, as the program advances. We also continue to advance our platform more broadly to bring RNA editing therapies to patients.” Recent Progress and Anticipated Upcoming Events AX-0810 Advancing Toward Target Engagement Data AX-0810, ProQR’s lead RNA editing program targeting NTCP, remains on track to report target engagement data from healthy volunteers in the second quarter of 2026. The Company has selected biliary atresia (BA) as the initial indication for Phase 2 development, based on strong biological rationale and high unmet need. As part of this strategy, ProQR plans to conduct an investigator-initiated trial (IIT) in pediatric participants with BA in China instead of the previously planned adult participant PSC cohort in its Phase 1 program. While PSC remains of interest as a potential setting for broader development, the Company is prioritizing a BA-focused IIT to provide a more direct path to early, data generation in the target patient population, prior to initiati...

Wall Street expects a year-over-year decline in earnings on higher revenues when ProQR (PRQR) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This Dutch drugmaker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -36.4%. Revenues are expected to be $5.53 million, up 10.8% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 6.98% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A posit...

AX-0810 Phase I target engagement data due this quarter — ProQR expects readout from its healthy-volunteer study later this quarter after first-cohort results showed favorable safety and PK, with a planned PSC patient cohort and Phase II targeted at biliary atresia to follow. AX-0811 is a next‑generation NTCP candidate driven by AI — ProQR says its AI-enabled discovery cut timelines dramatically and produced AX-0811 with much higher editing efficiency (~60% in humanized mice); management indicated a CTA and early clinical data are planned (timing described variably across presentations). New programs and funding runway — ProQR regained rights to AX-0422 for Hurler syndrome (CTA enabling now; CTA expected early 2027 with initial data H1 2027) and is advancing AX-2911 for PNPLA3-driven MASH via a China IIT, and the company says it is funded into mid-2027. Interested in ProQR Therapeutics N.V.? Here are five stocks we like better. ProQR Therapeutics (NASDAQ:PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA editing program AX-0810, a next-generation follow-on candidate (AX-0811), and the addition of two programs, AX-0422 for Hurler syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH). Chief Executive Officer Daniel de Boer said ProQR remains on track to report target engagement data from its ongoing Phase I healthy volunteer study of AX-0810 “later this quarter,” describing it as a key milestone designed to demonstrate engagement on bile acid transport. Chief Medical Officer Dr. Cristina López-López said initial data from the first cohort showed a “favorable safety and tolerability profile,” with pharmacokinetics consistent with non-clinical observations. → Levi Strauss Gains as DTC Continues to Fuel Revenue Growth AX-0810 targets NTCP, a bile acid transporter responsible for uptake from the bloodstream into the liver. López-López said AX-0810 is designed to convert wild-type NTCP into the protective Q68R variant to limit bile acid re-uptake into hepatocytes, aiming to reduce toxic bile acid accumulation that drives cholestatic liver diseases. The Phase I study’s biomarker-based target engagement strategy includes three readouts, according to López-López: Total bile acids in serum (with a two-fold increase describe...

LEIDEN, Netherlands (AP) — LEIDEN, Netherlands (AP) — ProQR Therapeutics NV (PRQR) on Thursday reported a loss of $9.1 million in its fourth quarter. On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 9 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 8 cents per share. The Dutch drugmaker posted revenue of $5.5 million in the period. For the year, the company reported a loss of $47.7 million, or 45 cents per share. Revenue was reported as $18 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRQR at https://www.zacks.com/ap/PRQR

Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026 Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3) Ended 2025 with € 92.4 million cash and cash equivalents and achieved $4.5 million in Eli Lilly collaboration milestones in 2025, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2025, and provided a business update. “2025 was a year of meaningful clinical progress for ProQR as we advanced AX-0810 for Cholestatic Diseases into a Phase 1 trial and continued to expand the reach of our Axiomer RNA editing platform and pipeline,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “With target engagement data for AX-0810 expected in the first half of 2026, we are approaching an important milestone for the Company and an important step toward bringing a new treatment closer to patients with cholestatic diseases.” De Boer continued, “In parallel to advancing AX-0810, we strengthened our pipeline with the selection of Development Candidates for AX-2402 in Rett syndrome and AX-2911 in MASH, and continued to advance our collaboration with Lilly, achieving $4.5 million in milestones during the year. As we enter 2026, our focus remains on delivering the AX-0810 target engagement data in the first half the year and advancing our innovative RNA editing therapies for patients with significant unmet need.” Recent Progress and Anticipated Upcoming Events AX-0810 – Phase 1 Progress and Upcoming Target Engagement Data AX-0810 uses Axiomer’s ability to modulate protein function by editing NTCP RNA for the treatment of cholestatic diseases, such as primary sclerosing cholangitis (PSC) and biliary atresia. AX-0810 is in a Phase 1 multiple-dose escalation study ongoing in healthy volunteers in the Netherlands. ProQR reported encouraging initial 4-week safety and pharmacokinetic data from the first cohort of healthy volunteers. Target engagement data in healthy volunteer cohorts is on track for the first half of 2026. Preparations are underway...

Kamada (KMDA) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -30.80%. A quarter ago, it was expected that this biopharmaceutical would post earnings of $0.1 per share when it actually produced earnings of $0.09, delivering a surprise of -10%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Kamada, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $44.68 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.29%. This compares to year-ago revenues of $39.01 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kamada shares have added about 26.9% since the beginning of the year versus the S&P 500's decline of 0.9%. While Kamada has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kamada was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here....

Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.83%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.09 per share when it actually produced earnings of $0.21, delivering a surprise of +133.33%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Puma Biotech, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $75.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 11.26%. This compares to year-ago revenues of $59.1 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Puma Biotech shares have added about 29.1% since the beginning of the year versus the S&P 500's gain of 1.5%. While Puma Biotech has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Puma Biotech was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of...

LEIDEN, Netherlands (AP) — LEIDEN, Netherlands (AP) — ProQR Therapeutics NV (PRQR) on Thursday reported a loss of $12.9 million in its third quarter. On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 12 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. The Dutch drugmaker posted revenue of $3.4 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRQR at https://www.zacks.com/ap/PRQR

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026 € 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2025, and provided a business update. “Last month we achieved an important milestone with the CTA authorization and are initiating our first-in-human study for AX-0810, marking a significant step forward for both this program and our Axiomer RNA editing platform,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “This study represents the first clinical evaluation of an Axiomer editing oligonucleotide and positions us to deliver initial safety and PK data before year-end, followed by target engagement data in the first half of 2026. Supported by our strong cash position providing runway into mid-2027, we continue to advance our broader pipeline, platform, and partnership activities, executing on our strategy to deliver transformative RNA editing therapies for diseases with high unmet need.” Recent Progress and Anticipated Upcoming Events In November, the Company hosted a virtual analyst and investor event focused on AX-0810, highlighting the Phase 1 trial design and target engagement/biomarker strategy. AX-0810 uses Axiomer’s ability to modulate protein function by targeting NTCP for the treatment of cholestatic diseases. In October AX-0810 received CTA authorization and a first-in-human (FIH) Phase 1 study is being initiated in healthy volunteers. Initial safety, tolerability, and PK data for Cohort 1 is expected toward the end of 2025 with target engagement data for all healthy volunteer cohorts in the first half of 2026. In parallel, activities are underway to include a patient cohort in this FIH following completion of the healthy volunteer cohorts. Beyond AX-0810, ProQR’s Axiomer pipeline demons...

LEIDEN, Netherlands (AP) — LEIDEN, Netherlands (AP) — ProQR Therapeutics NV (PRQR) on Thursday reported a loss of $13.8 million in its second quarter. The Leiden, Netherlands-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 8 cents per share. The Dutch drugmaker posted revenue of $4.3 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRQR at https://www.zacks.com/ap/PRQR

Explore ProQR Therapeutics's Fair Values from the Community and select yours Revenue: €3.98m (down 39% from 2Q 2024). Net loss: €12.2m (loss widened by 352% from 2Q 2024). €0.12 loss per share (further deteriorated from €0.033 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 50%. Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 4.3% from a week ago. Before you take the next step you should know about the 2 warning signs for ProQR Therapeutics that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.